クリティカルケア褥瘡評価ツール(CALCULATE)尺度のトルコ語版の妥当性および信頼性試験
Cansu Polat Dünya1, Nurten Özen1, Fatma Nur Ceylan2
1Internal Medicine Nursing Department, Faculty of Nursing, Istanbul University, Istanbul, Türkiye.
Aim:
The aim of this study was to translate the CALCULATE Scale into Turkish in adult intensive care unit (ICU) patients and assess its validity and reliability.
Method:
This study was conducted in a general ICU in Turkey. The CALCULATE and Braden scales were evaluated by two nurses at admission and reassessed daily for 72 h or until discharge, death or PI development. Concurrent validity was assessed using Pearson's correlation. Predictive validity was evaluated via ROC analysis, with sensitivity, specificity, AUC and optimal cut-off points calculated using Youden's Index. Interobserver agreement was examined using intraclass correlation coefficients.
Results:
In total, 728 assessments (364 CALCULATE and 364 Braden) were performed among 91 patients, resulting in a mean of 4.0 assessments per patient. The Turkish version of the CALCULATE Scale demonstrated excellent content validity (CVI = 0.97) and inter-rater reliability (ICC = 0.952). The CALCULATE Scale demonstrated superior predictive performance (AUC = 0.795) compared with the Braden Scale (AUC = 0.679), showing both higher specificity (78.38%) and greater sensitivity (64.81%). Furthermore, a significant inverse correlation (r = -0.701, p < 0.001) was found between the CALCULATE and Braden scores, confirming concurrent validity.
Conclusion:
The Turkish CALCULATE Scale is a valid and reliable instrument for assessing PI risk in adult ICU patients. Its integration into ICU practice can support early detection and timely prevention.
さらに関連する動画
06:45Development of a Benchtop Model for Evaluating the Compatibility of Wound Dressing Materials with Negative Pressure Wound Therapy Systems
Published on: May 2, 2025
10:39Qualitative and Quantitative Validation of Tools with Rating Scales Aimed at Assessing the Quality of University Service-Learning
Published on: August 29, 2025
